Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
RSV infection program accelerated
October 23rd, 2005
Alnylam Pharmaceuticals, Inc., (ALNY) updated its product pipeline guidance for the remainder of 2005. The company now expects to file an investigational new drug (IND) application for ALN-RSV01, its proprietary RNAi therapeutic candidate for RSV infection, with the Food and Drug Administration (FDA) by the end of the year, rather than in the first half of 2006 as previously forecast. In addition, given the reported efficacy in recent phase III studies from competing drugs targeting vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration (AMD), the company has made a strategic business decision to suspend...
Source: Medical Letter on the CDC & FDA (2005-10-23)
|
